NO312068B1 - Pyrrolidinylmetylindolsalt - Google Patents

Pyrrolidinylmetylindolsalt Download PDF

Info

Publication number: NO312068B1
Authority: NO; Norway
Prior art keywords: fumarate salt; compound; salt; methylpyrrolidin; ylmethyl
Prior art date: 1995-05-20

Application number

NO19975210A

Other languages

English (en)

Norwegian (no)

Other versions

NO975210L (no

NO975210D0 (no

Inventor

Martin James Wythes

Original Assignee

Pfizer Res And Dev Co Nv Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-20

Filing date

1997-11-13

Publication date

2002-03-11

1997-11-13 Application filed by Pfizer Res And Dev Co Nv Sa filed Critical Pfizer Res And Dev Co Nv Sa

1997-11-13 Publication of NO975210L publication Critical patent/NO975210L/no

1997-11-13 Publication of NO975210D0 publication Critical patent/NO975210D0/no

2002-03-11 Publication of NO312068B1 publication Critical patent/NO312068B1/no

Links

VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 31
BWQZTHPHLITOOZ-CQSZACIVSA-N n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C BWQZTHPHLITOOZ-CQSZACIVSA-N 0.000 claims description 6
239000001530 fumaric acid Substances 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
206010027599 migraine Diseases 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
230000000996 additive effect Effects 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000003814 drug Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
229940079593 drug Drugs 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 18
239000000203 mixture Substances 0.000 description 16
238000009472 formulation Methods 0.000 description 15
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000012458 free base Substances 0.000 description 11
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000010525 oxidative degradation reaction Methods 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000036542 oxidative stress Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000013590 bulk material Substances 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
TZQSNURHFSOKAI-WZGZYPNHSA-N (e)-but-2-enedioic acid;n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound OC(=O)\C=C\C(O)=O.C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C TZQSNURHFSOKAI-WZGZYPNHSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012297 crystallization seed Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000047 product Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000004441 surface measurement Methods 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrrole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO19975210A 1995-05-20 1997-11-13 Pyrrolidinylmetylindolsalt NO312068B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9510223.2A GB9510223D0 (en)	1995-05-20	1995-05-20	Therapeutic agent
PCT/EP1996/001560 WO1996036632A1 (fr)	1995-05-20	1996-04-10	Sel de methylpyrrolidinylindole

Publications (3)

Publication Number	Publication Date
NO975210L NO975210L (no)	1997-11-13
NO975210D0 NO975210D0 (no)	1997-11-13
NO312068B1 true NO312068B1 (no)	2002-03-11

Family

ID=10774766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975210A NO312068B1 (no)	1995-05-20	1997-11-13	Pyrrolidinylmetylindolsalt

Country Status (41)

Country	Link
US (1)	US5994387A (fr)
EP (1)	EP0827503B1 (fr)
JP (1)	JP3233940B2 (fr)
KR (1)	KR100295255B1 (fr)
CN (1)	CN1063175C (fr)
AP (1)	AP738A (fr)
AR (1)	AR003949A1 (fr)
AT (1)	ATE194986T1 (fr)
AU (1)	AU701154B2 (fr)
BG (1)	BG63046B1 (fr)
BR (1)	BR9610858A (fr)
CA (1)	CA2219631C (fr)
CO (1)	CO5040221A1 (fr)
CZ (1)	CZ287939B6 (fr)
DE (1)	DE69609504T2 (fr)
DK (1)	DK0827503T3 (fr)
DZ (1)	DZ2034A1 (fr)
ES (1)	ES2148753T3 (fr)
GB (1)	GB9510223D0 (fr)
GR (1)	GR3034290T3 (fr)
HR (1)	HRP960223B1 (fr)
HU (1)	HU217657B (fr)
IL (1)	IL118239A (fr)
IS (1)	IS1908B (fr)
LV (1)	LV11992B (fr)
MA (1)	MA23876A1 (fr)
MX (1)	MX9708966A (fr)
MY (1)	MY132066A (fr)
NO (1)	NO312068B1 (fr)
NZ (1)	NZ306448A (fr)
OA (1)	OA10747A (fr)
PL (1)	PL183142B1 (fr)
PT (1)	PT827503E (fr)
RU (1)	RU2161618C2 (fr)
SK (1)	SK281782B6 (fr)
TN (1)	TNSN96074A1 (fr)
TR (1)	TR199701397T1 (fr)
UA (1)	UA44320C2 (fr)
WO (1)	WO1996036632A1 (fr)
YU (1)	YU29496A (fr)
ZA (1)	ZA963938B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9825988D0 (en) *	1998-11-27	1999-01-20	Pfizer Ltd	Indole derivatives
US20100266638A1 (en) *	2004-02-26	2010-10-21	Allergan, Inc.	Headache treatment method
EP2875020B1 (fr) *	2012-07-19	2017-09-06	Boehringer Ingelheim International GmbH	Procédé de pràparation de une sel d'acide fumarique de la 9-[4-(3-chloro-2-fluoro-phénylamino)-7-méthoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undécan-5-one

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3906406C1 (fr) *	1989-03-01	1990-10-25	Goedecke Ag, 1000 Berlin, De
US5545644A (en) *	1990-10-15	1996-08-13	Pfizer Inc.	Indole derivatives
CA2091562C (fr) *	1990-10-15	2001-03-27	John Eugene Macor	Derives de l'indole
AP486A (en) *	1993-04-27	1996-04-16	Pfizer	Indole derivatives.

1995
- 1995-05-20 GB GBGB9510223.2A patent/GB9510223D0/en active Pending
1996
- 1996-04-10 TR TR97/01397T patent/TR199701397T1/xx unknown
- 1996-04-10 AU AU55005/96A patent/AU701154B2/en not_active Ceased
- 1996-04-10 MX MX9708966A patent/MX9708966A/es not_active IP Right Cessation
- 1996-04-10 WO PCT/EP1996/001560 patent/WO1996036632A1/fr not_active Ceased
- 1996-04-10 SK SK1541-97A patent/SK281782B6/sk unknown
- 1996-04-10 KR KR1019970708280A patent/KR100295255B1/ko not_active Expired - Fee Related
- 1996-04-10 PL PL96323143A patent/PL183142B1/pl unknown
- 1996-04-10 CA CA002219631A patent/CA2219631C/fr not_active Expired - Fee Related
- 1996-04-10 CZ CZ19973648A patent/CZ287939B6/cs not_active IP Right Cessation
- 1996-04-10 BR BR9610858A patent/BR9610858A/pt not_active Application Discontinuation
- 1996-04-10 AT AT96912013T patent/ATE194986T1/de not_active IP Right Cessation
- 1996-04-10 DE DE69609504T patent/DE69609504T2/de not_active Expired - Fee Related
- 1996-04-10 JP JP53448896A patent/JP3233940B2/ja not_active Expired - Fee Related
- 1996-04-10 EP EP96912013A patent/EP0827503B1/fr not_active Expired - Lifetime
- 1996-04-10 HU HU9801761A patent/HU217657B/hu not_active IP Right Cessation
- 1996-04-10 UA UA97126158A patent/UA44320C2/uk unknown
- 1996-04-10 NZ NZ306448A patent/NZ306448A/xx unknown
- 1996-04-10 RU RU97120998/04A patent/RU2161618C2/ru not_active IP Right Cessation
- 1996-04-10 DK DK96912013T patent/DK0827503T3/da active
- 1996-04-10 PT PT96912013T patent/PT827503E/pt unknown
- 1996-04-10 US US08/952,792 patent/US5994387A/en not_active Expired - Fee Related
- 1996-04-10 ES ES96912013T patent/ES2148753T3/es not_active Expired - Lifetime
- 1996-04-10 CN CN96194043A patent/CN1063175C/zh not_active Expired - Fee Related
- 1996-04-11 AP APAP/P/1996/000801A patent/AP738A/en active
- 1996-05-10 AR ARP960102519A patent/AR003949A1/es unknown
- 1996-05-13 IL IL11823996A patent/IL118239A/xx not_active IP Right Cessation
- 1996-05-16 HR HR960223A patent/HRP960223B1/xx not_active IP Right Cessation
- 1996-05-16 YU YU29496A patent/YU29496A/sh unknown
- 1996-05-17 ZA ZA9603938A patent/ZA963938B/xx unknown
- 1996-05-17 MA MA24243A patent/MA23876A1/fr unknown
- 1996-05-17 MY MYPI96001888A patent/MY132066A/en unknown
- 1996-05-17 TN TNTNSN96074A patent/TNSN96074A1/fr unknown
- 1996-05-17 CO CO96025158A patent/CO5040221A1/es unknown
- 1996-05-18 DZ DZ960077A patent/DZ2034A1/fr active
1997
- 1997-10-30 IS IS4605A patent/IS1908B/is unknown
- 1997-11-13 NO NO19975210A patent/NO312068B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102053A patent/BG63046B1/bg unknown
- 1997-11-20 OA OA70132A patent/OA10747A/en unknown
- 1997-12-11 LV LVP-97-256A patent/LV11992B/en unknown
2000
- 2000-08-30 GR GR20000401977T patent/GR3034290T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP9801761A2 (hu)	1999-05-28
AP738A (en)	1999-03-23
AR003949A1 (es)	1998-09-30
PL183142B1 (pl)	2002-05-31
CA2219631C (fr)	2001-01-23
DE69609504T2 (de)	2000-12-14
RU2161618C2 (ru)	2001-01-10
CN1063175C (zh)	2001-03-14
JPH10506639A (ja)	1998-06-30
PT827503E (pt)	2000-11-30
ZA963938B (en)	1997-11-17
HU217657B (hu)	2000-03-28
DZ2034A1 (fr)	2002-07-21
BG63046B1 (bg)	2001-02-28
PL323143A1 (en)	1998-03-16
CZ287939B6 (cs)	2001-03-14
NZ306448A (en)	1998-10-28
IL118239A0 (en)	1996-09-12
CN1185152A (zh)	1998-06-17
MX9708966A (es)	1998-03-31
ATE194986T1 (de)	2000-08-15
CO5040221A1 (es)	2001-05-29
HK1017884A1 (en)	1999-12-03
KR19990014934A (ko)	1999-02-25
LV11992A (lv)	1998-03-20
LV11992B (en)	1998-06-20
EP0827503A1 (fr)	1998-03-11
WO1996036632A1 (fr)	1996-11-21
MA23876A1 (fr)	1996-12-31
BG102053A (en)	1998-06-30
TNSN96074A1 (fr)	2005-03-15
NO975210L (no)	1997-11-13
AU5500596A (en)	1996-11-29
JP3233940B2 (ja)	2001-12-04
AU701154B2 (en)	1999-01-21
KR100295255B1 (ko)	2001-08-07
HRP960223A2 (en)	1997-10-31
IS4605A (is)	1997-10-30
OA10747A (en)	2002-12-11
GR3034290T3 (en)	2000-12-29
ES2148753T3 (es)	2000-10-16
IS1908B (is)	2003-12-31
EP0827503B1 (fr)	2000-07-26
HUP9801761A3 (en)	1999-06-28
CZ364897A3 (cs)	1998-11-11
DK0827503T3 (da)	2000-11-20
BR9610858A (pt)	1999-07-13
TR199701397T1 (xx)	1998-03-21
SK281782B6 (sk)	2001-07-10
MY132066A (en)	2007-09-28
SK154197A3 (en)	1999-01-11
HRP960223B1 (en)	2000-12-31
UA44320C2 (uk)	2002-02-15
AP9600801A0 (en)	1996-04-30
YU29496A (sh)	1998-12-23
NO975210D0 (no)	1997-11-13
CA2219631A1 (fr)	1996-11-21
GB9510223D0 (en)	1995-07-19
IL118239A (en)	2000-10-31
US5994387A (en)	1999-11-30
DE69609504D1 (de)	2000-08-31

Legal Events

Date	Code	Title	Description
2004-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO326965B1 (no)	2009-03-23	a-form eller β-form-krystall av acetanilid-derivat og farmasoytisk preparat
IL100091A (en)	1998-08-16	Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
EP1935892B1 (fr)	2010-08-11	Dérivés d'acide glycyrrhétinique-30-amide et applications
KR100667721B1 (ko)	2007-01-15	제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
US8202898B1 (en)	2012-06-19	Pharmaceutical composition
WO2015158298A1 (fr)	2015-10-22	Cristal, procédé de préparation et utilisation associées
US12492192B2 (en)	2025-12-09	Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
US20080234323A1 (en)	2008-09-25	Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
WO2008085674A1 (fr)	2008-07-17	Compositions pharmaceutiques comprenant des co-cristaux de célécoxib
AU701154B2 (en)	1999-01-21	Pyrrolidinyl methyl indole salt
US20210363101A1 (en)	2021-11-25	Crystalline forms of gft-505, processes for preparation and use thereof
AU2016236659B9 (en)	2019-05-02	AHU377 crystal form, preparation method and use thereof
CN104974141A (zh)	2015-10-14	咔唑四唑类衍生物及其制备方法和应用
JPH032183A (ja)	1991-01-08	ビスベンジルイソキノリン誘導体
JPH0368578A (ja)	1991-03-25	ビスベンジルイソキノリン誘導体
WO2025035486A1 (fr)	2025-02-20	Sel pharmaceutiquement acceptable et forme cristalline d'un inhibiteur de tyrosine kinase et son procédé de préparation
JPH0368557A (ja)	1991-03-25	ビスべンジルイソキノリン誘導体
Karagiannidou	0	Setting Specifications for polymorphs in the Pharmaceutical Industry
WO2005023789A1 (fr)	2005-03-17	Sel phosphorique de l'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique